产品说明

一般描述

A cell-permeable second generation hybrid polar agent that acts as a histone deacetylase (HDAC) inhibitor. The HDAC inhibition is believed to arise as a result of the binding of the hydroxamic moiety to the active site zinc. Shown to be a potent inducer of transformed cell growth arrest and terminal differentiation (~4 µM). Induces apoptosis and the CD95/CD95-Ligand expression in human neuroblastoma cells, which can be blocked by Caspase Inhibitor Z-VAD-FMK (Cat. No. 627610).
A cell-permeable second generation hybrid polar agent that acts as a histone deacetylase (HDAC) inhibitor. The HDAC inhibition is believed to arise as a result of the binding of the hydroxamic moiety to the active site zinc. Shown to be a potent inducer of transformed cell growth arrest and terminal differentiation (~4 µM). Induces apoptosis and the CD95/CD95-Ligand expression in human neuroblastoma.

包装

5 mg in Plastic ampoule
Packaged under inert gas

生化/生理作用

Cell permeable: yes
Primary Target
HDAC
Product does not compete with ATP.
Reversible: no

警告

Toxicity: Standard Handling (A)

重悬

Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 6 months at -20°C.

其他说明

Coffey, D.C., et al. 2001. Cancer Res.61, 3591.
Coffey, D.C., et al. 2000. Pediatr. Oncol.35, 577.
Marks, P.A., et al. 2000. J. Natl. Cancer Inst.92, 1210.
Glick, R.D., et al. 1999. Cancer Res.59, 4392.
Richon, V.M., et al. 1998. Proc. Natl. Acad. Sci. USA95, 3003.
Richon, V.M., et al. 1996. Proc. Natl. Acad. Sci. USA93, 5705.

法律信息

Not available for sale in the United States.
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

基本信息

产品性质

安全信息